Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

被引：0
|
作者：
Cavo, Michele
Iida, Shinsuke
Blade, Joan
Mateos, Maria-Victoria
Lee, Je-Jung
Garg, Mamta
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8031
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma.
    San Miguel, J. F.
    Schlag, R.
    Khuageya, N.
    Shpilberg, O.
    Dimopoulos, M.
    Kropff, M.
    Spicka, L.
    Petrucci, M.
    Sarrioilova, O.
    Dmoszynska, A.
    Abdulkadyrov, K.
    Schots, R.
    Jiang, B.
    Palumbo, A.
    Mateos, M.
    Liu, K.
    Cakana, A.
    Van de Velde, H.
    Richardson, P.
    BLOOD, 2007, 110 (11) : 31A - 31A
  • [22] Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study
    Dimopoulos, Meletios A.
    Richardson, Paul
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Shpilberg, Ofer
    Kastritis, Efstathios
    Kropff, Martin H.
    Petrucci, Maria Teresa
    Delforge, Michel
    Alexeeva, Julia A.
    Schots, Rik
    Masszi, Tamas
    Mateos, Maria-Victoria
    Deraedt, William
    Liu, Kevin
    Cakana, Andrew
    van de Velde, Helgi
    Miguel, Jesus F. San
    BLOOD, 2008, 112 (11) : 608 - 609
  • [23] Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies
    Cavo, Michele
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Mateos, Maria-Victoria
    Jakubowiak, Andrzej
    Deraedt, William
    Lam, Annette
    Kampfenkel, Tobias
    Qi, Ming
    He, Jianming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 480 - 489
  • [24] Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Dmide
    Cavalli, Maide
    Ria, Roberto
    Gentilini, Silvia
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Vincelli, Donatella
    Baldini, Luca
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Pautasso, Chiara
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Cangialosi, Clotilde
    Mansueto, Giovanna
    Liberati, Anna Marina
    Magarotto, Valeria
    Omede, Paola
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [25] COST-EFFECTIVENESS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) VERSUS BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP)
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Ervin-Haynes, A.
    Marek, J.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Monzini, M. S.
    Facon, T.
    HAEMATOLOGICA, 2014, 99 : 379 - 379
  • [26] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
    Morabito, Fortunato
    Bringhen, Sara
    Larocca, Alessandra
    Wijermans, Pierre
    Victoria Mateos, Maria
    Gimsing, Peter
    Mazzone, Carla
    Gottardi, Daniela
    Omede, Paola
    Zweegman, Sonja
    Jose Lahuerta, Juan
    Zambello, Renato
    Musto, Pellegrino
    Magarotto, Valeria
    Schaafsma, Martijn
    Oriol, Albert
    Juliusson, Gunnar
    Cerrato, Chiara
    Catalano, Lucio
    Gentile, Massimo
    Isabel Turel, Ana
    Liberati, Anna Marina
    Cavalli, Maide
    Rossi, Davide
    Passera, Roberto
    Rosso, Stefano
    Beksac, Meral
    Cavo, Michele
    Waage, Anders
    San Miguel, Jesus
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    Offidani, Massimo
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362
  • [27] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Lee, Jae Hoon
    Moreau, Philippe
    Niesvizky, Ruben
    Dimopoulos, Meletios
    Hajek, Roman
    Pour, Ludek
    Jurczyszyn, Artur
    Qiu, Lugui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Osman, Muhtarjan
    Paiva, Bruno
    San-Miguel, Jesus
    BLOOD, 2019, 133 (18) : 1953 - 1963
  • [28] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Magarotto, Valeria
    Di Raimondo, Francesco
    Ria, Roberto
    Offidani, Massimo
    Nozzoli, Chiara
    Patriarca, Francesca
    Callea, Vincenzo
    Benevolo, Giulia
    Marasca, Roberto
    Guglielmelli, Tommasina
    Rizzo, Manuela
    Grasso, Mariella
    Petrucci, Maria Teresa
    Omede, Paola
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 243 - 243
  • [29] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
    Palumbo, A.
    Bringhen, S.
    Rossi, D.
    Ria, R.
    Berretta, S.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Levi, A.
    Guglielmelli, T.
    Benevolo, G.
    Callea, V.
    Liberati, A. M.
    Crippa, C.
    Di Renzo, N.
    Catalano, L.
    De Sabbata, G.
    Rizzi, R.
    Feo, C.
    Mazza, R.
    Farina, G.
    Spadano, A.
    Pisani, F.
    Podda, L.
    Aitoro, G.
    Magarotto, V.
    Astolfi, M.
    Di Raimondo, F.
    Gaidano, G.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
  • [30] Real-life experience of the combination of daratumumab, bortezomib, melphalan, and prednisone (DVMP) in patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation
    Domingo-Gonzalez, Amalia
    Alonso, Rafael
    de Soto Alvarez, Teresa
    Lerma, Ana
    Martin Moro, Fernando
    Sanchez-Pina, Jose
    Pradillo Fernandez, Virginia
    Landete, Elena
    Velasco Valdazo, Alberto E.
    Menendez Cuevas, Marina
    Lopez Rinon, Monica Maria
    Ramirez Lopez, Andres
    Lopez-Garcia, Alberto
    Lazaro del Campo, Paula
    Ruiz Gomez, Fabio Augusto
    Jesus Blanchard, Maria
    Askari, Elham
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S144 - S144
12345